Chemomab Therapeutics (CMMB) Competitors $1.68 +0.06 (+3.70%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CMMB vs. NVCT, EPRX, RANI, ANIX, ASRT, ADAG, PWUP, CTMX, ME, and ANLShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Nuvectis Pharma (NVCT), Eupraxia Pharmaceuticals (EPRX), Rani Therapeutics (RANI), Anixa Biosciences (ANIX), Assertio (ASRT), Adagene (ADAG), PowerUp Acquisition (PWUP), CytomX Therapeutics (CTMX), 23andMe (ME), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Nuvectis Pharma Eupraxia Pharmaceuticals Rani Therapeutics Anixa Biosciences Assertio Adagene PowerUp Acquisition CytomX Therapeutics 23andMe Adlai Nortye Chemomab Therapeutics (NASDAQ:CMMB) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership. Is CMMB or NVCT more profitable? Chemomab Therapeutics' return on equity of -101.70% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% Nuvectis Pharma N/A -155.80%-104.02% Which has more volatility & risk, CMMB or NVCT? Chemomab Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Do institutionals and insiders believe in CMMB or NVCT? 46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor CMMB or NVCT? In the previous week, Nuvectis Pharma had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for Nuvectis Pharma and 0 mentions for Chemomab Therapeutics. Nuvectis Pharma's average media sentiment score of 1.94 beat Chemomab Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Overall Sentiment Chemomab Therapeutics Neutral Nuvectis Pharma Very Positive Do analysts recommend CMMB or NVCT? Chemomab Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 346.43%. Nuvectis Pharma has a consensus target price of $21.00, suggesting a potential upside of 364.60%. Given Nuvectis Pharma's higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, CMMB or NVCT? Nuvectis Pharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$1.00-1.68Nuvectis PharmaN/AN/A-$22.26M-$1.16-3.90 Does the MarketBeat Community favor CMMB or NVCT? Chemomab Therapeutics received 9 more outperform votes than Nuvectis Pharma when rated by MarketBeat users. However, 90.00% of users gave Nuvectis Pharma an outperform vote while only 64.29% of users gave Chemomab Therapeutics an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1864.29% Underperform Votes1035.71% Nuvectis PharmaOutperform Votes990.00% Underperform Votes110.00% SummaryChemomab Therapeutics beats Nuvectis Pharma on 8 of the 15 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.12M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.6810.5990.0517.18Price / SalesN/A195.801,117.14116.99Price / CashN/A57.1643.0437.86Price / Book1.095.094.784.78Net Income-$24.22M$151.83M$120.31M$225.60M7 Day Performance6.33%-2.13%-1.92%-1.23%1 Month Performance1.82%-3.10%11.51%3.36%1 Year Performance253.31%11.54%30.61%16.60% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.3163 of 5 stars$1.68+3.7%$7.50+346.4%+242.9%$24.12MN/A-1.6820Positive NewsNVCTNuvectis Pharma3.2411 of 5 stars$4.83+2.8%$21.00+334.8%-44.0%$93.32MN/A-4.058Positive NewsEPRXEupraxia Pharmaceuticals2.2152 of 5 stars$3.40-1.2%$9.00+164.7%N/A$92.76MN/A-4.7829Positive NewsRANIRani Therapeutics3.4519 of 5 stars$1.62-2.7%$11.71+625.0%-55.4%$92.56M$2.72M-1.57110ANIXAnixa Biosciences2.949 of 5 stars$2.83-0.7%$8.50+200.4%-29.0%$91.07M$210,000.00-7.315ASRTAssertio3.3686 of 5 stars$0.95+3.3%$3.25+242.1%-18.7%$90.70M$125.76M-1.2620Gap DownADAGAdagene1.9972 of 5 stars$2.02-1.9%$5.00+147.5%+18.5%$89.43M$815,746.000.00260PWUPPowerUp AcquisitionN/A$11.43flatN/A+1.6%$88.81MN/A0.00N/ACTMXCytomX Therapeutics4.321 of 5 stars$1.13+1.8%$5.77+410.8%-22.7%$88.43M$101.21M6.53170News CoveragePositive NewsME23andMe2.3629 of 5 stars$3.35flat$9.40+180.6%-80.8%$87.50M$219.64M-0.13770Positive NewsANLAdlai Nortye1.583 of 5 stars$2.36+3.1%$9.00+281.4%-75.5%$87.08M$5M0.00127Positive NewsGap Up Related Companies and Tools Related Companies NVCT Competitors EPRX Competitors RANI Competitors ANIX Competitors ASRT Competitors ADAG Competitors PWUP Competitors CTMX Competitors ME Competitors ANL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMMB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMMB Stock Alerts